Abstract

Objective: To explore the application value of brain natriuretic peptide in the clinical treatment of cardiovascular diseases. Methods: Choose 48 patients with cardiovascular diseases treated in our hospital from March 2015 to March 2016 and divide them into the treatment group and control group according to different treatment drugs and there are 24 cases in each group. The control group was treated with astragaloside IV, and the treatment group was treated with brain natriuretic peptide. Then compare their treatment effect, rehospitalization rate, the time of angina pectoris induced by exercise, the concentration of serum brain natriuretic peptide in patients under different cardiac function status between two groups. Results: The clinical effect of treatment group was better than the control group. The readmission rate was lower than the control group. The time of inducing angina pectoris by exercise was longer than the control group. The concentration of brain natriuretic peptide of the patients under different cardiac function status was better improved than the control group.The difference between them was significant (P<0.05) and has statistical significance. Conclusion: It is of great significance to use brain natriuretic peptide in patients with cardiovascular disease which can improve the treatment effect, reduce the readmission rate of patients, prolong the time of angina induced by exercise, improve the concentration of brain natriuretic peptide of the patients in different cardiac functional status and provide a outstanding basis for patients in clinical treatment of the disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.